SNA 004
Alternative Names: SNA-004; SNA004 Solid tumor imagingLatest Information Update: 22 Jul 2022
At a glance
- Originator SmartNuclide Biopharma
- Class Antineoplastics; Diagnostic agents; Radiopharmaceuticals
- Mechanism of Action Diagnostic imaging enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Jul 2022 Preclinical trials in Solid tumours (Diagnosis) in China (unspecified route) (SmartNuclide Biopharma pipeline, July 2022)
- 01 Dec 2021 Early research in Solid tumours (Diagnosis) in China (unspecified route) (SmartNuclide Biopharma pipeline, December 2021)